8 Coupons
-
Special Offer
-
30% off
suven life sciences' pashamylaram facility successfully completes usfda inspection
.-
.
.
- eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
the media are there to give credibility to society and its structures. that�s why they�re called �major� instead of �minor.� . .
johns hopkins all children's hospital. [jim damaske |times]